Symptom management in metastatic breast cancer

Oncologist

Volumn 16, Issue 9, 2011, Pages 1203-1214

  Irvin Jr , William ^a   Muss, Hyman B ^a   Mayer, Deborah K ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Metastatic breast cancer; Palliative care; Symptom management; Treatment

Indexed keywords

AMFEBUTAMONE; ANTIEMETIC AGENT; CHLORPROMAZINE; CODEINE; DENOSUMAB; DESIPRAMINE; DIAZEPAM; DOCUSATE SODIUM; DRONABINOL; DULOXETINE; FENTANYL; GABAPENTIN; HYDROCODONE; HYDROMORPHONE; IMIPRAMINE; LIDOCAINE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE; OXYCODONE; OXYMORPHONE; PARACETAMOL; PREGABALIN; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; ZALEPLON; ZOLPIDEM TARTRATE;

ADRENAL METASTASIS; ANOREXIA; ANXIETY; ARTICLE; BLEEDING; BONE METASTASIS; BONE PAIN; BRACHIAL PLEXUS NEUROPATHY; BRAIN METASTASIS; BREAST CANCER; CANCER LOCALIZATION; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CONFUSION; CONSTIPATION; COUGHING; CRANIAL NERVE PARALYSIS; DEPRESSION; DIARRHEA; DRUG DOSE INCREASE; DYSPNEA; EVENING DOSAGE; FATIGUE; HEADACHE; HEART METASTASIS; HEMOPTYSIS; HOSPICE CARE; HUMAN; HYPERCALCEMIA; INFECTION; JAUNDICE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHEDEMA; MENTAL DISEASE; METASTASIS POTENTIAL; MORNING DOSAGE; NAUSEA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; PAIN; PATHOLOGIC FRACTURE; PHYSICAL ACTIVITY; PLEURA METASTASIS; PREVALENCE; PRIORITY JOURNAL; SATIETY; SEIZURE; SLEEP DISORDER; SOCIAL SUPPORT; SPEECH DISORDER; SYMPTOMATOLOGY; VISCERAL METASTASIS; VOMITING; WEAKNESS;

BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; PALLIATIVE CARE; QUALITY OF LIFE;

EID: 80053187998     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0159     Document Type: Article

References (101)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 2.2011. Available at http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf, accessed August 10, 2011.
3. Surveillance, Epidemiology, and End Results (SEER). Cancer of the Breast. SEER Stat Fact Sheets 2008, based on November 2007 SEER data submission, posted to the SEER Web site 2008. Available at http://seer. cancer.gov, accessed August 10, 2011.
4. Beslija S, Bonneterre J, Burstein HJ et al. Third consensus on medical treatmentof metastatic breast cancer. Ann Oncology 2009;20:1771-1785.
5. Hayes D. Evaluation after primary therapy. In: Harris JR, Lippman ME, Morrow M et al., eds. Diseases of the Breast. Philadelphia: Lippincott Williams & Wilkins, 2000:709.
6. Hellman S, Harris J. Natural history of breast cancer. In: Harris JR, Lip-pman ME, Morrow M et al., eds. Diseasesofthe Breast. Philadelphia: Lip-pincott Williams & Wilkins, 2000:407.
7. Luoma ML, Hakamies-Blomqvist L. The meaning of quality of life in patients being treated for advanced breast cancer: A qualitative study. Psychooncology 2004;13:729-739.
8. Mayer M, Hunis A, Oratz R et al. Lessons Learned From the Metastatic Breast Cancer Community. Semin Oncol Nurs 2010;26:195-202.
9. Bower JE. Behavioral symptoms in patients with breast cancer and survivors. J Clin Oncol 2008;26:768-777.
10. Kenne Sarenmalm E, Ohlén J, Jonsson T et al. Coping with recurrent breast cancer: Predictors of distressing symptoms and health-related quality of life. J Pain Symptom Manage 2007;34:24-39.
11. Aranda S, Schofield P, Weih L et al. Mapping the qualityof life and unmet needs of urban women with metastatic breast cancer. Eur J Cancer Care 2005;14:211-222.
12. Goudas LC, Bloch R, Gialeli-Goudas M et al. The epidemiology of cancer pain. Cancer Invest 2005;23:182-190.
13. Treede RD, Jensen TS, Campbell JN et al. Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Neurology 2008; 70:1630-1635.
14. Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999;353: 1695-1700.
15. Dy SM, Asch SM, Naeim A et al. Evidence-based standards for cancer pain management. J Clin Oncol 2008;26:3879-3885.
16. Taillibert S, Laigle-Donadey F, Chodkiewicz C et al. Leptomeningeal me-tastases from solid malignancy: A review. J Neurooncol 2005;75:85-99.
17. Chang EL, Lo S. Diagnosis and management of central nervous system metastases from breast cancer. The Oncologist 2003;8:398-410.
18. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007;(4):CD005454.
19. Moore RA, Straube S, Wiffen PJ et al. Pregabalin for acute and chronic pain in adults. Cochrane Database of Syst Rev 2009;(3):CD007076.
20. Moore RA, Wiffen PJ, Derry S et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2011;(3): CD007938.
21. Hollingshead J, Dhmke RM, Cornblath DR. Tramadol for neuropathic pain. Cochrane Database Syst Rev 2006;3:CD003726.
22. National Comprehensive Cancer Network (NCCN). Adult Cancer Pain. Available at http://www.nccn.org/professionals/physician_gls/pdf/pain.pdf, accessed August 10, 2011.
23. Hoskin PJ, Ford HT, Harmer CL. Hemibody irradiation (HBI) for meta-static bone pain in two histologically distinct groups of patients. Clin Oncol (R Coll Radiol) 1989;1:67-69.
24. Ural AU, Avcu F, Baran Y. Bisphosphonate treatment and radiotherapy in metastatic breast cancer. Med Oncol 2008;25:350-355.
25. Hoskin PJ. Bisphosphonates and radiation therapy for palliation of meta-static bone disease. Cancer Treat Rev 2003;29:321-327.
26. Hoskin PJ, Stratford MR, Folkes LK et al. Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet 2000;355: 1428-1429.
27. Gangi A, Dietemann JL, Schultz A et al. Interventional radiologic procedures with CT guidance in cancer pain management. Radiographics 1996; 16:1289-1304; discussion 1304-1306.
28. McNicol E, Horowicz-Mehler N, Fisk RA et al. Management of opioid side effects in cancer-related and chronic noncancer pain: A systematic review. J Pain 2003;4:231-256.
29. Leonard R, Hardy J, van Tienhoven G et al. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. J Clin Oncol 2001;19:4150-4159.
30. Mitchell SA, Beck SL, Hood LE et al. Putting evidence into practice: Evidence-based interventions for fatigue during and following cancer and its treatment. Clin J Oncol Nurs 2007;11:99-113.
31. Wanchai A, Armer JM, Stewart BR. Nonpharmacologic supportive strategies to promote quality of life in patients experiencing cancer-related fatigue. Clin J Oncol Nurs 2011;15:203-214.
32. Svensson H, Brandberg Y, Einbeigi Z et al. Psychological reactions to progression of metastatic breast cancer-an interview study. Cancer Nurs 2009;32:55.
33. Warren M. Uncertainty, lack of control and emotional functioning in women with metastatic breast cancer: A review and secondary analysis of the literature using the critical appraisal technique. Eur J Cancer Care 2010;19:564-574.
34. Kissane DW, Grabsch B, Love A et al. Psychiatric disorder inwomen with early stage and advanced breast cancer: A comparative analysis. Aust N Z J Psychiatry 2004;38:320-326.
35. Desmarais JE, Looper KJ. Managing menopausal symptoms and depression in tamoxifen users: Implications of drug and medicinal interactions. Maturitas 2010;67:296-308.
36. Kelly CM, Juurlink DN, Gomes T et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: A population based cohort study. BMJ 2010;340:c693.
37. Gonzalez-Santiago S, Zarate R, Haba-Rodríguez J et al. CYP2D6*4 polymorphism as blood predictive biomarker of breast cancer relapse in patients receiving adjuvant tamoxifen. J Clin Oncol 2007;25(18 suppl):590.
38. Goetz MP, Knox SK, Suman VJ et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007;101:113-121.
39. Aubert RE, Stanek EJ, Yao J et al. Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. J Clin Oncol 2009; 27(9 suppl):CRA508.
40. Rae JM, Drury S, Hayes DF et al. Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial [abstract S1-7]. Presented at the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 9, 2010.
41. Fiorentino L, Ancoli-Israel S. Insomnia and its treatment in women with breast cancer. Sleep Med Rev 2006;10:419-429.
42. Lis CG, Gupta D, Grutsch JF. The relationship between insomnia and patient satisfaction with quality of life in cancer. Support Care Cancer 2008; 16:261-266.
43. Page MS, Berger AM, Johnson LB. Putting evidence into practice: Evidence-based interventions for sleep-wake disturbances. Clin J Oncol Nurs 2006;10:753-767.
44. Berger AM. Updateon the state ofthe science: Sleep-wake disturbances in adult patients with cancer. Oncol Nurs Forum 2009;36:E165-E177.
45. Michael S, Charikleia S, Konstantinos K. Lymphedema and breast cancer: A review of the literature. Breast Cancer 2011;18:174-180.
46. Nesvold IL, Reinertsen KV, Fosså SD et al. The relation between arm/ shoulder problems and quality of life in breast cancer survivors: A cross-sectional and longitudinal study. J Cancer Surviv 2011;5:62-72.
47. Rourke LL, Hunt KK, Cormier JN. Breast cancer and lymphedema:Acur-rent overview for the healthcare provider. Womens Health (London) 2010;6:399-406.
48. Poage E, Singer M, Armer J et al. Demystifying lymphedema: Development of the lymphedema putting evidence into practice card. Clin J Oncol Nurs 2008;12:951-964.
49. Ahmed Omar MT, El Morsy AM, Abd-El-Gayed Ebid A. Treatment of post-mastectomy lymphedema with laser therapy: Double blind placebo control randomized study. J Surg Res 2011;165:82-90.
50. Lau RWL, Cheing GLY. Managing postmastectomy lymphedema with low-level laser therapy. Photomed Laser Surg 2009;27:763-769.
51. Vassard D, Olsen MH, Zinckernagel L et al. Psychological consequences of lymphoedema associated with breast cancer: A prospective cohort study. Eur J Cancer 2010;46:3211-3218.
52. Shikama N, Sekiguchi K, Nakamura N. Management of locoregional recurrence of breast cancer. Breast Cancer 2010 May 7 [Epub ahead of print].
53. Leonard R, Hardy J, van Tienhoven G et al. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. J Clin Oncol 2001;19:4150-4159.
54. Adderley U, Smith R. Topical agents and dressings for fungating wounds. Cochrane Database Syst Rev 2007;(2):CD003948.
55. Paul JC, Pieper BA. Topical metronidazole for the treatment of wound odor: A review of the literature. Ostomy Wound Manage 2008;54:18-27.
56. Thomas JR, von Gunten CF. Management of dyspnea. J Support Oncol 2003;1:23-32; discussion 32-34.
57. Reuben DB, Mor V. Dyspnea in terminally ill cancer patients. Chest 1986; 89:234-236.
58. Lower EE, Baughman RP. Pulmonary lymphangitic metastasis from breast cancer. Lymphocytic alveolitis is associated with favorable prognosis. Chest 1992;102:1113-1117.
59. Goldsmith HS, Bailey HD, Callahan EL et al. Pulmonary lymphangitic metastases from breast carcinoma. Arch Surg 1967;94:483-488.
60. Gibson PG, Bryant DH, Morgan GW et al. Radiation-induced lung injury: A hypersensitivity pneumonitis? Ann Intern Med 1988;109:288-291.
61. Nagata S, Ueda N, Yoshida Y et al. Severe interstitial pneumonitis associated with the administration of taxanes. J Infect Chemother 2010;16: 340-344.
62. Shoemaker LK, Estfan B, Induru R et al. Symptom management: An important part of cancer care. Cleve Clin J Med 2011;78:25-34.
63. Abernethy AP, Currow DC, Frith P et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003;327:523-528.
64. Lorenz KA, Lynn J, Dy SM et al. Evidence for improving palliative care at the end of life: A systematic review. Ann Intern Med 2008;148:147-159.
65. Coyne PJ, Viswanathan R, Smith TJ. Nebulized fentanyl citrate improves patients' perception of breathing, respiratory rate, and oxygen saturation in dyspnea. J Pain Symptom Manage 2002;23:157-160.
66. Polosa R, Simidchiev A, Walters EH. Nebulised morphine for severe interstitial lung disease. Cochrane Database Syst Rev 2002;(3):CD002872.
67. Navigante AH, Cerchietti LC, Castro MA et al. Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. J Pain Symptom Manage 2006;31:38-47.
68. Ripamonti C, Fulfaro F, Bruera E. Dyspnoea in patients with advanced cancer: Incidence, causes and treatments. Cancer Treat Rev 1998;24: 69-80.
69. Clemens KE, Quednau I, Klaschik E. Use of oxygen and opioids in the palliation of dyspnoea in hypoxic and non-hypoxic palliative care patients: A prospective study. Support Care Cancer 2009;17:367-377.
70. Qaseem A, Snow V, Shekelle P et al. Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2008;148:141-146.
71. DiSalvo WM, Joyce MM, Tyson LB et al. Putting evidence into practice: Evidence-based interventions for cancer-related dyspnea. Clin J Oncol Nurs 2008;12:341-352.
72. Apffelstaedt JP, Van Zyl JA, Muller AG. Breast cancer complicated by pleural effusion: Patient characteristics and results of surgical management. J Surg Oncol 1995;58:173-175.
73. Bielsa S, Hernàndez P, Rodriguez-Panadero F et al. Tumor type influences the effectiveness of pleurodesis in malignant effusions. Lung 2011; 189:151-155.
74. Sioris T, Sihvo E, Salo J et al. Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis. Eur J Surg Oncol 2009;35:546-551.
75. Jensen AØ, Jacobsen JB, Nørgaard M et al. Incidence of bone metastases and skeletal-related events in breast cancer patients: A population-based cohort study in Denmark. BMC Cancer 2011;11:29.
76. Hosking DJ, Cowley A, Bucknall CA. Rehydration in the treatment of severe hypercalcaemia. Q J Med 1981;50:473-481.
77. Major P, Lortholary A, Hon J et al. Zoledronic acid is superior to pamidro-nate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558-567.
78. Wisneski LA. Salmon calcitonin in the acute management of hypercalcemia. Calcif Tissue Int 1990;46(suppl):S26-S30.
79. Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zole-dronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 2010;28: 5132-5139.
80. Van Poznak CH, Temin S, Yee GC et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011;29:1221-1227.
81. George R, Jeba J, Ramkumar G et al. Interventions for the treatment of metastatic extradural spinal cord compression in adults. Cochrane Database Syst Rev 2008;(4):CD006716.
82. Stephenson J, Davies A. An assessment of aetiology-based guidelines for the managementof nausea and vomiting in patients with advanced cancer. Support Care Cancer 2006;14:348-353.
83. Currow DC, Coughlan M, Fardell B et al. Use of ondansetron in palliative medicine. J Pain Symptom Manage 1997;13:302-307.
84. Dy SM, Apostol CC. Evidence-based approaches to other symptoms in advanced cancer. Cancer J 2010;16:507-513.
85. Donnelly S, Walsh D. The symptoms of advanced cancer. Semin Oncol 1995;22(suppl 3):67-72.
86. Yamagishi A, Morita T, Miyashita M et al. The care strategy for families of terminally ill cancer patients who become unable to take nourishment orally: Recommendations from a nationwide survey of bereaved family members' experiences. J Pain Symptom Manage 2010;40:671-683.
87. Adams LA, Shepard N, Caruso RA et al. Putting evidence into practice: Evidence-based interventions to prevent and manage anorexia. Clin J Oncol Nurs 2009;13:95-102.
88. Mercadante S, Fulfaro F, Casuccio A. The use of corticosteroids in home palliative care. Support Care Cancer 2001;9:386-389.
89. Loprinzi CL, Ellison NM, Schaid DJ et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990;82:1127-1132.
90. Jatoi A, Windschitl HE, Loprinzi CL et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: A North Central Cancer Treatment Group study. J Clin Oncol 2002;20:567-573.
91. Winter SM. Terminal nutrition: Framing the debate for the withdrawal of nutritional support in terminally ill patients. Am J Med 2000;109:723-726.
92. Stephenson J, Gilbert J. The development of clinical guidelines on paracentesis for ascites related to malignancy. Palliat Med 2002;16:213-218.
93. Anders CK, Peppercorn J. Treating in the dark: Unanswered questions on costs and benefits of late line therapy for metastatic breast cancer. Cancer Investig 2009;27:13-16.
94. Earle CC, Landrum MB, Souza JM et al. Aggressiveness of cancer care near the end of life: Is it a quality-of-care issue? J Clin Oncol 2008;26: 3860-3866.
95. Epstein R, Street R Jr. Patient-Centered Communication in Cancer Care: Promoting Healing and Reducing Suffering. NIH Publication No. 07-6225. Bethesda, MD: National Cancer Institute, 2007:1-203.
96. Temel JS, Greer JA, Muzikansky A et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733-742.
97. Behl D, Jatoi A. What do oncologists say about chemotherapy at the very end of life? Results from a semiqualitative survey. J Palliat Med 2010;13: 831-835.
98. American Society of Clinical Oncology. Advanced Cancer Care Planning: What Patients and Their Families Need to Know About Their Choices When Facing Serious Illness. Available at http://www.cancer.net/patient/Coping/Advanced%20Cancer%20Care%20Planning/Advanced_Cancer_ Care_Planning.pdf, accessed August 10, 2011.
99. Mazanec P, Daly B, Ptorak E et al. A new model of palliative care for oncology patients with advanced disease. J Hosp Palliat Nurs 2009;11: 324-331.
100. National Comprehensive Cancer Network (NCCN). NCCN Guidelines -Fatigue, version 1/2011. Available at http://www.nccn.org/professionals/ physician_gls/pdf/fatigue.pdf, accessed August 10, 2011.
101. ®). Management. Available at http://www.cancer.gov/cancertopics/pdq/supportivecare/sleepdisorders/ HealthProfessional/page4#Section_74, accessed August 10, 2011.